MoonLake Immunotherapeutics (MLTX) Equity Average (2021 - 2026)

MoonLake Immunotherapeutics' Equity Average history runs 6 years deep, the most recent figure standing at $279.3 million for Q1 2026.

• In Q1 2026, Equity Average fell 35.01% year-over-year to $279.3 million; the TTM figure through Mar 2026 stood at $279.3 million (down 35.01% YoY), while the FY2025 annual figure was $375.7 million, down 21.76% from the prior year.
• Equity Average was $279.3 million for Q1 2026 at MoonLake Immunotherapeutics, down from $296.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $541.2 million in Q2 2024 to a low of -$18.5 million in Q1 2022.
• Historically, Equity Average has averaged $311.3 million across 5 years, with a median of $323.4 million in 2025.
• Biggest YoY gain for Equity Average was 11775.35% in 2022; the steepest drop was 1236.66% in 2022.
• A 5-year view of Equity Average shows it stood at $75.7 million in 2022, then surged by 562.86% to $501.6 million in 2023, then decreased by 6.06% to $471.2 million in 2024, then tumbled by 37.03% to $296.7 million in 2025, then fell by 5.88% to $279.3 million in 2026.
• The last three Equity Average figures came in at $279.3 million (Q1 2026), $296.7 million (Q4 2025), and $323.4 million (Q3 2025), per Business Quant data.